P-069 Can PET CT Scans Be Used as a Predictor of Response to Treatment With Anti-TNF Agents in Patients With Crohn’s Disease?

2014 ◽  
Vol 20 ◽  
pp. S54-S55
Author(s):  
Swaminath Arun ◽  
Lameka Katherine ◽  
Ichise Masanori
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Response To Treatment ◽  
Ct Scans ◽  
Pet Ct

scholarly journals Outcomes of surgical treatment in patients with anorectal fistula cancer

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Katsuya Osone ◽  
Hiroomi Ogawa ◽  
Chika Katayama ◽  
Yuta Shibasaki ◽  
Kunihiko Suga ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Mucinous Adenocarcinoma ◽  
Fdg Pet ◽  
R0 Resection ◽  
Anorectal Fistula ◽  
Patients With Cancer ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Fdg Accumulation

Abstract Background No standard treatment for anorectal fistula cancer, such as multidisciplinary therapy, has been established due to the rarity of the disease. Herein, we investigated patients with cancer associated with anorectal fistula who underwent surgery to clarify the clinicopathological characteristics and to propose future perspectives for treatment strategies. Case presentation Seven patients with cancer associated with anorectal fistula who underwent rectal amputation in our institute were analyzed with regard to clinical characteristics, pathological findings, surgical results, and prognosis. Four cases had Crohn's disease as an underlying cause. All seven cases were diagnosed as advanced stage. Preoperative [18F]-fluoro-2-deoxy-d-glucose (FDG)-positron emission tomography/computed tomography (FDG-PET/CT) showed abnormal FDG accumulation in six cases including four mucinous adenocarcinomas. Three cases that received preoperative hyperthermo-chemoradiotherapy achieved pathological R0 resection. Postoperative recurrence was observed in four cases including three with Crohn's disease and one resulting in death. Conclusions Anorectal fistula cancer is rare and difficult to be diagnosed at early stages. Mucinous adenocarcinoma associated with anorectal fistula tends to exhibit abnormal FDG accumulation by FDG-PET/CT unlike common colorectal mucinous adenocarcinoma. Preoperative hyperthermo-chemoradiotherapy may be effective in obtaining pathological complete resection.

Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric Crohn’s disease

2018 ◽  
Vol 48 (11-12) ◽  
pp. 1242-1250 ◽  
Author(s):  
Tomer Ziv-Baran ◽  
Séamus Hussey ◽  
Malgorzata Sladek ◽  
Jorge Amil Dias ◽  
Javier Martin de Carpi ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Disease Severity ◽  
Response To Treatment ◽  
Early Relapse ◽  
Paediatric Crohn’S Disease ◽  
New Onset

T1222 Small Animal PET-CT as a Non-Invasive Method to Evaluate Terminal Ileal Inflammation in a Murine Model of Crohn's Disease

2010 ◽  
Vol 138 (5) ◽  
pp. S-514-S-515 ◽  
Author(s):  
Pieter Hindryckx ◽  
Steven Staelens ◽  
Steven Deleye ◽  
Harald Peeters ◽  
Debby Laukens ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Murine Model ◽  
Small Animal ◽  
Small Animal Pet ◽  
Animal Pet ◽  
Non Invasive ◽  
Pet Ct ◽  
Invasive Method

Crohn's disease presenting as multiple pulmonary nodules in FDG PET/CT scan

2015 ◽  
Vol 26 (3) ◽  
pp. 279-280
Author(s):  
Mevlut Kurt ◽  
Emrah Posul ◽  
Guray Can ◽  
Bulent Yilmaz ◽  
Ugur Korkmaz ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Ct Scan ◽  
Fdg Pet ◽  
Pulmonary Nodules ◽  
Multiple Pulmonary Nodules ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Pet Ct Scan

scholarly journals Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis—A Prospective Polish Population Study

2021 ◽  
Vol 10 (22) ◽  
pp. 5311
Author(s):  
Anna Pękala ◽  
Rafał Filip
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Response To Therapy ◽  
Response To Treatment ◽  
Induction Treatment ◽  
Therapeutic Drug ◽  
Induction Phase ◽  
Drug Levels ◽  
Trough Levels

Background: Primary lack or secondary loss of response to therapy with infliximab is a significant problem. This study aimed to evaluate the response to treatment in patients with Crohn’s disease (CD) and ulcerative colitis (UC) achieving therapeutic and sub-therapeutic trough levels of biosimilar infliximab (CT-P13). Results: A total of 65 patients (32 with CD and 33 with UC) were recruited. The overall response rate in both CD and UC patients exceeded 80%. There were no significant differences in treatment response and CT-P13 levels for patients with CD or UC. We did not find significant differences in the percentage of patients achieving drug levels of 3 μg/mL at week 6, 10, or 12; a significant decrease was observed at week 14. Up to 55.5% of patients with CD and 64.3% of patients with UC with sub-therapeutic CT-P13 levels at week 14 primarily responded to treatment. Conclusions: Intermediate measurements of drug levels at weeks 10 and 12 did not capture any pronounced decrease in infliximab concentrations below therapeutic levels in either group, thus suggesting no clinical usefulness. A significant percentage of patients primarily responded to treatment despite sub-therapeutic drug levels after the induction phase.

scholarly journals ASSESSMENT OF THE RESPONSE OF PATIENTS WITH CROHN'S DISEASE TO BIOLOGICAL THERAPY USING NEW NON-INVASIVE MARKERS: lactoferrin and calprotectin

2013 ◽  
Vol 50 (2) ◽  
pp. 130-137 ◽  
Author(s):  
Islaine Martins NOGUEIRA ◽  
Sender Jankiel MISZPUTEN ◽  
Orlando AMBROGINI Jr. ◽  
Ricardo ARTIGIANI-NETO ◽  
Cláudia Teresa CARVENTE ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Biological Therapy ◽  
Activity Index ◽  
Maintenance Phase ◽  
Disease Activity Index ◽  
Inflammatory Activity ◽  
Response To Treatment ◽  
Significant Difference ◽  
Fecal Markers

Context The use of fecal markers to monitor Crohn's disease is crucial for assessing the response to treatment. Objective To assess the inflammatory activity of Crohn's disease by comparing fecal markers (calprotectin and lactoferrin), colonoscopy combined with biopsy, and the Crohn's disease activity index (CDAI), as well as serum markers, before treatment with infliximab, after the end of induction, and after the end of maintenance. Methods Seventeen patients were included who had been previously diagnosed with Crohn's disease and were using conventional treatment but required the introduction of biological therapy with infliximab. Each patient underwent a colonoscopy with biopsy, serum, and fecal (calprotectin and lactoferrin) tests to assess inflammatory activity, and CDAI assessments before treatment with infliximab, after induction (week 8), and after maintenance (week 32). Results The calprotectin levels exhibited significant reductions (P = 0.04) between the assessment before treatment with infliximab and the end of induction, which did not occur after the end of the maintenance phase. Lactoferrin remained positive throughout the three phases of the study. Regarding the histological assessment, a significant difference was found only between the assessment before treatment and after the end of maintenance (P = 0.036), and 60% of the patients exhibited histological improvements after the completion of the follow-up period. The CDAI exhibited a significant difference between the assessment before treatment with infliximab and after induction, as well as before treatment and after maintenance (P<0.01). Conclusion Calprotectin and lactoferrin are not useful for monitoring inflammatory activity in Crohn's disease patients who are subjected to biological therapy.

scholarly journals Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease

2019 ◽  
Vol 8 (10) ◽  
pp. 1646 ◽  
Author(s):  
Davide Giuseppe Ribaldone ◽  
Gian Paolo Caviglia ◽  
Amina Abdulle ◽  
Rinaldo Pellicano ◽  
Maria Chiara Ditto ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Gut Microbiota ◽  
Response To Treatment ◽  
Biologic Drugs ◽  
Therapeutic Success ◽  
Bacterial Phyla ◽  
Reactive Protein ◽  
Adalimumab Therapy ◽  
A Prospective Study

The response to treatment with biologic drugs, in patients with Crohn’s disease, could be associated with changes in gut microbiota composition. The aim of our study was to analyse the modification of microbiota during adalimumab therapy in patients with Crohn’s disease. We performed a prospective study in patients with Crohn’s disease analysing gut microbiota before start of adalimumab therapy (T0) and after six months of therapy (T1). Among the 20 included patients, the phylum Proteobacteria fell from 15.7 ± 3.5% at T0 to 10.3 ± 3.4% at T1 (p = 0.038). Furthermore, the trend in relation to therapeutic success was analysed. Regarding bacterial phyla, Proteobacteria decreased in patients in whom therapeutic success was obtained, passing from a value of 15.8% (± 4.6%) to 6.8 ± 3.1% (p = 0.049), while in non-responder patients, percentages did not change (T0 = 15.6 ± 5.7%, T1 = 16.8 ± 7.6%, p = 0.890). Regarding the Lachnospiraceae family, in patients with normalization of C reactive protein six 6 months of adalimumab therapy, it increased from 16.6 ± 3.1% at T0 to 23.9 ± 2.6% at T1 (p = 0.049). In conclusion, in patients who respond to Adalimumab therapy by decreasing inflammation, there is a trend of intestinal eubiosis being restored.

Sign in / Sign up

Export Citation Format

Share Document